Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
eXoZymes ( (EXOZ) ) just unveiled an update.
On January 29, 2026, eXoZymes reported results from a 100-liter pilot production run of N‑trans‑caffeoyltyramine (NCT), a naturally occurring compound of interest in lipid metabolism and energy utilization research, achieving about 99% reaction conversion, 91% process recovery, a 90% isolated yield and 535 grams of NCT at 99.6% pharma-grade purity. The run, executed end-to-end by Cayman Chemical under a transferred protocol, demonstrated that the exozyme-based, cell-free process not only scales with improved performance but also delivers highly pure NCT without co-producing closely related contaminants that typically complicate cell-based manufacture, thereby validating the robustness and transferability of eXoZymes’ platform and enabling the company to supply pilot-scale quantities for partner-led formulation development and application testing.
The most recent analyst rating on (EXOZ) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on eXoZymes stock, see the EXOZ Stock Forecast page.
Spark’s Take on EXOZ Stock
According to Spark, TipRanks’ AI Analyst, EXOZ is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, widening losses, and accelerating cash burn) and bearish technical signals (price below key moving averages with negative MACD). A positive offset comes from the recent production scale-up milestone, while valuation is difficult to interpret due to the company’s losses and negative P/E.
To see Spark’s full report on EXOZ stock, click here.
More about eXoZymes
Founded in 2019, Los Angeles-based eXoZymes Inc. is a synthetic biology company that develops AI-enhanced, cell-free enzyme systems, or “exozymes,” to convert sustainable biomass into high-value chemicals, nutraceuticals and medicines, positioning itself as a next-generation, eco-friendly alternative to traditional petrochemical and cell-based biomanufacturing processes.
Average Trading Volume: 3,966
Technical Sentiment Signal: Strong Sell
See more insights into EXOZ stock on TipRanks’ Stock Analysis page.